ALFA Finder| Revenue growth | 28% YoY growth driven by formulation and EU sales. |
|---|---|
| Margins | EBITDA margins healthy at 28%, aided by formulation mix. |
| Order book | Firm orders in place for Q4, especially for Nor-UDCA. |
| Demand visibility | Strong traction in oncology and non-oncology API segments. |
| Management confidence | Balanced; shift from investment phase to asset monetization and execution. |
Growth
Revenue grew 28% YoY to ₹411cr; EBITDA rose 41% to ₹115cr with 28% margins.
Outlook
Targeting 150cr+ annual licensing income; Albumin commercialization expected in India by FY28.
Risks
High debt levels and pending USFDA clearance for the Jadcherla facility remain key overhangs.
Earnings Call filed with NSE, NSE: SHILPAMED. Summary written with AI assistance from the document.
Shilpa Medicare Ltd: key numbers
- Share price
- ₹934.15
- Market cap
- ₹18,270 Cr
- Revenue (annual)
- ₹1,539 Cr
- Net profit (annual)
- ₹243.3 Cr
- P/E (TTM)
- 55.0×Sector 43.8×
- Promoter holding
- 40.13%+0.00% QoQ
- FII holding
- 12.11%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shilpa Medicare Ltd
All →Shilpa Medicare Earnings Call Transcript: Key Takeaways
Record Q2 revenue of ₹538 Cr (+35%) and EBITDA of ₹151 Cr (28% margin), but gross margin fell roughly 700 bps and management deflected several key questions.
Shilpa Medicare Insolvency Petition
Shilpa Medicare reports NCLAT set aside the CIRP against its subsidiary FTF Pharma, annulling the process. The filing states no impact on the listed entity.
Shilpa Medicare Investor Presentation: Key Takeaways
Q2 FY27 revenue INR 538 cr (+45% YoY), EBITDA INR 151 cr (28% margin), PAT INR 79 cr (+80%). 1HFY27 total income INR 1,007 cr (+44%). Strategy: complex FDF launches, CDMO, biologics, rHA.
Shilpa Medicare Q2 FY27 Results: Net Profit ₹79.2 Cr, Up 79.6% YoY
Shilpa Medicare Ltd reported revenue from operations of ₹529.1 Cr (+43.0% YoY) and net profit of ₹79.2 Cr (+79.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹79.2 Cr · +79.6% YoY
Shilpa Medicare Board Meeting Date
Shilpa Medicare's board meeting is scheduled for 5 November 2026 to approve Q2 and H1 unaudited financial results. The trading window remains closed until 7 November 2026.
Shilpa Medicare Business Update
Shilpa Medicare Limited’s Unit 4 in Jadcherla received GMP certification from AGES, Austria, following a successful inspection. This milestone enables operations for European and global markets.